Pharmaceutical

ADCs breach barriers to become mainstream cancer treatment

Manufacturing practices are evolving to advance antibody drug conjugates (ADCs) for cancer treatment through a targeted approach.

Dec 17, 2024 - 06:00
ADCs breach barriers to become mainstream cancer treatment
Manufacturing practices are evolving to advance antibody drug conjugates (ADCs) for cancer treatment through a targeted approach.
Read the original article

Tags:

Previous Article

GSK’s lung cancer therapy gains EMA PRIME designation

Next Article

FDA approves Galderma’s Nemluvio to treat atopic dermatitis

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Denifanstat by Sagimet Biosciences for Breast Cancer: L...

Oct 27, 2023

We wish we’d written that: STAT staffers share their favorite stories of 2023

We wish we’d written that: STAT staffers share their fa...

Dec 29, 2023

Phase III study halted: Ferrer’s oral edaravone disappoints in ALS

Phase III study halted: Ferrer’s oral edaravone disappo...

Jan 31, 2024